---
title: "Leukemoid reactions: causes, blood-film clues and prognostic signals"
id: "cmaj-2-leukemoid-reactions-practice"
canonical_url: "https://medichelpline.com/clinical-feed/cmaj-2-leukemoid-reactions-practice"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "CMAJ"
source_url: "http://www.cmaj.ca/cgi/content/short/198/39/E1505?rss=1"
published_at: "2026-11-10T05:05:21.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Leukemoid reactions: causes, blood-film clues and prognostic signals
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cmaj-2-leukemoid-reactions-practice
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** CMAJ
- **Source URL:** [Original Journal Publication](http://www.cmaj.ca/cgi/content/short/198/39/E1505?rss=1)
- **Published At:** 2026-11-10T05:05:21.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Leukemoid reactions are marked, nonmalignant elevations in white blood cell count; most studies use a threshold above 25 × 10^9/L but no universally accepted cut-off exists. - Case series place incidence in hospitalized adults at roughly 0.5%–1%, with investigators reporting in-hospital mortality approaching 40% and higher mortality when leukocytosis persists beyond 24 hours. - Infectious triggers predominate; authors noted **Clostridioides difficile** and tuberculosis among important infectious etiologies, and the reaction can follow surgery, trauma, hemorrhage, or metastatic marrow involvement. - Drug exposures including granulocyte colony-stimulating factor and systemic corticosteroids are documented precipitants, as are systemic inflammatory conditions. - Peripheral smear typically shows neutrophilia, a left shift and immature granulocytes with rare or absent blasts; toxic granulation, Döhle bodies and thrombocytosis may be present. - Eosinophilia, basophilia or monocytosis on smear favour an underlying hematologic malignancy rather than a reactive process, investigators reported. - After secondary causes are sought, testing for the **BCR-ABL1** fusion gene is recommended to exclude chronic myelogenous leukemia. - Urgent hematology consultation is indicated for splenomegaly, leukocyte counts >100 × 10^9/L, increased blasts, morphologic dysplasia or persistent leukocytosis despite treatment of secondary causes. - Data indicated that the poor prognosis is usually driven by the underlying illness causing the reaction, often with end-organ damage and multiorgan failure.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://www.cmaj.ca/content/198/39/E1505#main-content) [![top-left](https://www.cmaj.ca/sites/default/files/2025-06/cmaj-logo_publisher.png) ](https://www.cmaj.ca/) ## Umbrella menu * [CMAJ Open](http://www.cmajopen.ca) * [CJS](http://www.canjsurg.ca) * [JAMC](https://www.cmaj.ca/page/apropos) * [Log in](https://www.cmaj.ca/openid-connect/sams-sigma/login-redirect?prompt=login&openid_connect_destination=/content/198/39/E1505) Toggle navigation menu Open settings menu Open search [![logo](https://www.cmaj.ca/sites/default/files/logo/cmaj-rgb_new_0_18.png)](https://www.cmaj.ca/) [![logo](https://www.cmaj.ca/sites/default/files/2025-05/cmaj-rgb_new.png)](https://www.cmaj.ca/) [ Advanced Search ](https://www.cmaj.ca/search) ## Main navigation * [Home](https://www.cmaj.ca/) * [Content](https://www.cmaj.ca/content/current) * [Current Issue](https://www.cmaj.ca/content/current) * [Past issues](https://www.cmaj.ca/content/by/year) * [Early releases](https://www.cmaj.ca/earlyrelease) * [Collections](https://www.cmaj.ca/collection) * [Sections](https://www.cmaj.ca/sections) * [Blog](http://cmajblogs.com/) * [Podcasts](https://www.cmaj.ca/page/multimedia/podcasts) * [COVID-19 articles](https://www.cmaj.ca/covid-19) * [Obituary notices](https://www.cmaj.ca/content/by/section/obituaries) * [Authors & Reviewers](https://www.cmaj.ca/page/content/overview-authors) * [Overview for authors](https://www.cmaj.ca/page/content/overview-authors) * [Submission guidelines](https://www.cmaj.ca/submission-guidelines) * [Submit a manuscript](https://mc.manuscriptcentral.com/cmaj) * [Forms](https://www.cmaj.ca/content/forms) * [Editorial process](https://www.cmaj.ca/content/editorial-process) * [Editorial policies](https://www.cmaj.ca/content/editorial-policies) * [Peer review process](https://www.cmaj.ca/content/peer-review-process) * [Publication fees](https://www.cmaj.ca/content/publication-fees) * [Reprint requests](https://www.cmaj.ca/content/reprint-requests) * [Open access](https://www.cmaj.ca/page/copyright) * [Patient engagement](https://www.cmaj.ca/Patient-Engagement) * [Physicians & Subscribers](https://www.cmaj.ca/content/about-us) * [Benefits for Canadian physicians](https://www.cmaj.ca/page/content/physician-benefits) * [CPD Credits for Canadian Physicians](https://www.cmaj.ca/page/content/earning-cpd-credits) * [Current Certified CPD Articles](https://www.cmaj.ca/content/current-certified-cpd-articles) * [Subscribe to email alerts](https://www.cmaj.ca/email-alerts) * [Subscribe to CMAJ print](https://www.cmaj.ca/subscribers) * [Subscription prices](https://www.cmaj.ca/page/subscription-prices) * [Obituary notices](https://www.cmaj.ca/obituaries) * [Email alerts](https://www.cmaj.ca/email-alerts) * [Subscribe to email alerts](https://www.cmaj.ca/email-alerts) * [JAMC](https://www.cmaj.ca/page/jamc/archives) * [À propos](https://www.cmaj.ca/page/apropos) * [Numéro en cours](https://www.cmaj.ca/novembre2026) * [Archives](https://www.cmaj.ca/page/jamc/archives) * [Sections](https://www.cmaj.ca/page/jamc-sections) * [Abonnement](https://www.cmaj.ca/page/abonnement) * [Alertes](https://www.cmaj.ca/page/alertes) * [Trousse média 2026](https://www.cmaj.ca/sites/default/files/additional-assets/site/pdfs/ads/2026/2026-JAMC-Media-Kit-r1.pdf) * [Avis de décès](https://www.cmaj.ca/avis-de-deces) * [CMAJ JOURNALS](https://www.cmaj.ca/) * [CMAJ Open](http://www.cmajopen.ca) * [CJS](http://www.canjsurg.ca) * [JAMC](https://www.cmaj.ca/page/apropos) [ ](https://www.facebook.com/CMAJ.JAMC "Follow on Facebook")[ ](https://www.instagram.com/cmaj.ca "Follow on Instagram")[ ](https://bsky.app/profile/cmaj.ca "Follow on Bluesky")[ ](https://www.buzzsprout.com/1815691 "Follow Podcast") [ Advanced Search ](https://www.cmaj.ca/search) * [Log in](https://www.cmaj.ca/openid-connect/sams-sigma/login-redirect?prompt=login&openid_connect_destination=/content/198/39/E1505) [![logo](https://www.cmaj.ca/sites/default/files/logo/cmaj-rgb_new_0_18.png)](https://www.cmaj.ca/) [![logo](https://www.cmaj.ca/sites/default/files/2025-05/cmaj-rgb_new.png)](https://www.cmaj.ca/) * Practice # Leukemoid reactions * Nickrooz Grami Nickrooz Grami * Department of Medicine (Grami, Dhamko, Gold), University of Toronto; Division of Hematology (Dhamko) and Divisions of Infectious Diseases and General Internal Medicine (Gold), Toronto General Hospital, Toronto, Ont. * MD * [Find this author on Google Scholar](https://www.cmaj.ca/lookup/google-scholar?link_type=googlescholar&gs_type=author&author\[0\]=Nickrooz%2BGrami "Open in new tab") * [Find this author on PubMed](https://www.cmaj.ca/lookup/external-ref?apath=/cmaj/198/39/E1505.atom&link_type=AUTHORSEARCH&access_num=Grami%20N) * [Search for this author on this site](https://www.cmaj.ca/search/?author1=Nickrooz%20Grami) * Helena Dhamko Helena Dhamko * Department of Medicine (Grami, Dhamko, Gold), University of Toronto; Division of Hematology (Dhamko) and Divisions of Infectious Diseases and General Internal Medicine (Gold), Toronto General Hospital, Toronto, Ont. * MD * [Find this author on Google Scholar](https://www.cmaj.ca/lookup/google-scholar?link_type=googlescholar&gs_type=author&author\[0\]=Helena%2BDhamko "Open in new tab") * [Find this author on PubMed](https://www.cmaj.ca/lookup/external-ref?apath=/cmaj/198/39/E1505.atom&link_type=AUTHORSEARCH&access_num=Dhamko%20H) * [Search for this author on this site](https://www.cmaj.ca/search/?author1=Helena%20Dhamko) * and Wayne L. Gold Wayne L. Gold * Department of Medicine (Grami, Dhamko, Gold), University of Toronto; Division of Hematology (Dhamko) and Divisions of Infectious Diseases and General Internal Medicine (Gold), Toronto General Hospital, Toronto, Ont. * MD * [Find this author on Google Scholar](https://www.cmaj.ca/lookup/google-scholar?link_type=googlescholar&gs_type=author&author\[0\]=Wayne%2BL.%2BGold "Open in new tab") * [Find this author on PubMed](https://www.cmaj.ca/lookup/external-ref?apath=/cmaj/198/39/E1505.atom&link_type=AUTHORSEARCH&access_num=Gold%20WL) * [Search for this author on this site](https://www.cmaj.ca/search/?author1=Wayne%20L.%20Gold) * CMAJ * November 10, 2026 * 198 * (39) * E1505; * DOI: https://doi.org/10.1503/cmaj.260791 [PDF](https://www.cmaj.ca/content/cmaj/198/39/E1505.full.pdf)[Help](https://scholar.google.com/scholar/help.html#access) * [Article](https://www.cmaj.ca/content/198/39/E1505#tab-group-article) * [Related Content](https://www.cmaj.ca/content/198/39/E1505#tab-group-related) * [Responses](https://www.cmaj.ca/content/198/39/E1505#tab-group-eletter) * [Metrics](https://www.cmaj.ca/content/198/39/E1505#tab-group-metrics) * [ PDF](https://www.cmaj.ca/content/cmaj/198/39/E1505.full.pdf) ## Leukemoid reactions are severe elevations of the leukocyte count that are not secondary to hematologic malignancies[1](https://www.cmaj.ca/content/198/39/E1505#ref-1) Almost all studies have used a leukocyte threshold of greater than 25 × 109/L to define leukemoid reactions; however, no universally accepted cut-off exists, and leukemoid reactions are best understood in their clinical context. The incidence of leukemoid reactions varies by population, with case series suggesting that they occur in 0.5% to 1% of all hospitalized adult patients.[1](https://www.cmaj.ca/content/198/39/E1505#ref-1) Overall in-hospital mortality rates approach 40% and may be nearly 60% in patients with reactions lasting more than 1 day.[1](https://www.cmaj.ca/content/198/39/E1505#ref-1) ## These reactions have a variety of underlying causes Infections are the most common triggers, with _Clostridioides difficile_ infection and tuberculosis being notable etiologies.[1](https://www.cmaj.ca/content/198/39/E1505#ref-1) Other causes include exposure to granulocyte colony-stimulating factor and systemic corticosteroids, metastatic carcinomatosis with bone marrow involvement (leukoerythroblastic reaction), surgery, trauma, hemorrhage, and systemic inflammatory conditions (Appendix 1, available at [www.cmaj.ca/lookup/doi/10.1503/cmaj.260791/tab-related-content](https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260791/tab-related-content)).[2](https://www.cmaj.ca/content/198/39/E1505#ref-2),[3](https://www.cmaj.ca/content/198/39/E1505#ref-3) History and physical examination should guide investigations for these causes. Leukemoid reactions can also coexist with underlying myeloid neoplasms. ## Peripheral blood film findings can indicate a leukemoid reaction Such reactions typically demonstrate neutrophilia, a left shift, immature granulocytes, and rare or absent blasts.[4](https://www.cmaj.ca/content/198/39/E1505#ref-4) Toxic granulations, Döhle bodies, and thrombocytosis may be present. Eosinophilia, basophilia, or monocytosis are more suggestive of hematologic malignancy.[4](https://www.cmaj.ca/content/198/39/E1505#ref-4) ## Leukemoid reactions can mimic chronic myelogenous leukemia and chronic neutrophilic leukemia After investigating for secondary causes, testing for the _BCR-ABL1_ fusion gene should be conducted to exclude chronic myelogenous leukemia. Urgent hematology consultation is indicated in patients with splenomegaly, a leukocyte count of more than 100 × 109/L, elevated blasts, morphologic dysplasia, or persistent leukocytosis despite treating secondary causes.[3](https://www.cmaj.ca/content/198/39/E1505#ref-3) ## Prognosis is poor despite treatment of the cause Inciting conditions often result in end-organ damage and multiorgan failure. The high risk of death is usually driven by the patient’s underlying illness rather than the leukocytosis itself.[1](https://www.cmaj.ca/content/198/39/E1505#ref-1),[5](https://www.cmaj.ca/content/198/39/E1505#ref-5) ## Footnotes * Competing interests: None declared. * This article has been peer reviewed. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: ## References 1. 1 [↵](https://www.cmaj.ca/content/198/39/E1505#xref-ref-1-1 "View reference in text") PotasmanIGrupperM. Leukemoid reaction: spectrum and prognosis of 173 adult patients. Clin Infect Dis 2013;57:e177–81. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Leukemoid%20reaction%3A%20spectrum%20and%20prognosis%20of%20173%20adult%20patients&author=I%20Potasman&author=M%20Grupper&publication_year=2013&journal=Clin%20Infect%20Dis&volume=57&pages=e177-81)[OpenURL](https://www.cmaj.ca/content/198/39/{openurl}?query=rft.jtitle%3DClin+Infect+Dis&rft_id%3Dinfo%3Adoi%2F10.1093%2Fcid%2Fcit562&rft_id%3Dinfo%3Apmid%2F23994818&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[CrossRef](https://dx.doi.org/10.1093/cid/cit562)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=23994818&dopt=Abstract) 2. 2 [↵](https://www.cmaj.ca/content/198/39/E1505#xref-ref-2-1 "View reference in text") KarakonstantisSKoulouridiMPitsillosK. A prospective study of hospitalized patients with leukemoid reaction; causes, prognosis and value of manual peripheral smear review. Rom J Intern Med 2019;57(3):241–7. [Google Scholar](https://scholar.google.com/scholar_lookup?title=A%20prospective%20study%20of%20hospitalized%20patients%20with%20leukemoid%20reaction%3B%20causes%2C%20prognosis%20and%20value%20of%20manual%20peripheral%20smear%20review&author=S%20Karakonstantis&author=M%20Koulouridi&author=K%20Pitsillos&publication_year=2019&journal=Rom%20J%20Intern%20Med&volume=57&issue=3&pages=241-7)[OpenURL](https://www.cmaj.ca/content/198/39/{openurl}?query=rft.jtitle%3DRom+J+Intern+Med&rft.volume%3D57&rft.spage%3D241&rft_id%3Dinfo%3Apmid%2F30862764&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=30862764&dopt=Abstract) 3. 3 [↵](https://www.cmaj.ca/content/198/39/E1505#xref-ref-3-1 "View reference in text") RileyLKRupertJ. Evaluation of patients with leukocytosis. Am Fam Physician 2015;92:1004–11. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Evaluation%20of%20patients%20with%20leukocytosis&author=LK%20Riley&author=J%20Rupert&publication_year=2015&journal=Am%20Fam%20Physician&volume=92&pages=1004-11)[OpenURL](https://www.cmaj.ca/content/198/39/{openurl}?query=rft.jtitle%3DAm+Fam+Physician&rft.volume%3D92&rft.spage%3D1004&rft_id%3Dinfo%3Apmid%2F26760415&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=26760415&dopt=Abstract) 4. 4 [↵](https://www.cmaj.ca/content/198/39/E1505#xref-ref-4-1 "View reference in text") HrizatAGongJZ. Comparison of blood cell counts in leukemoid reaction and chronic myeloid leukemia: a study using Scopio blood cell counter with statistical analysis. Int J Lab Hematol 2024;46:1125–7. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Comparison%20of%20blood%20cell%20counts%20in%20leukemoid%20reaction%20and%20chronic%20myeloid%20leukemia%3A%20a%20study%20using%20Scopio%20blood%20cell%20counter%20with%20statistical%20analysis&author=A%20Hrizat&author=JZ%20Gong&publication_year=2024&journal=Int%20J%20Lab%20Hematol&volume=46&pages=1125-7)[OpenURL](https://www.cmaj.ca/content/198/39/{openurl}?query=rft.jtitle%3DInt+J+Lab+Hematol&rft.volume%3D46&rft.spage%3D1125&rft_id%3Dinfo%3Apmid%2F39004772&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=39004772&dopt=Abstract) 5. 5 [↵](https://www.cmaj.ca/content/198/39/E1505#xref-ref-5-1 "View reference in text") PortichJPFaulhaberGA. Leukemoid reaction: a 21st-century cohort study. Int J Lab Hematol 2020;42(2):134–9. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Leukemoid%20reaction%3A%20a%2021st-century%20cohort%20study&author=JP%20Portich&author=GA%20Faulhaber&publication_year=2020&journal=Int%20J%20Lab%20Hematol&volume=42&issue=2&pages=134-9)[OpenURL](https://www.cmaj.ca/content/198/39/{openurl}?query=rft.jtitle%3DInt+J+Lab+Hematol&rft.volume%3D42&rft.spage%3D134&rft_id%3Dinfo%3Apmid%2F31765058&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=31765058&dopt=Abstract) ![Loading](https://www.cmaj.ca/modules/freebird/modules/highwire/highwire_markup/images/tab_loading.gif) ![Loading](https://www.cmaj.ca/modules/freebird/modules/highwire/highwire_markup/images/tab_loading.gif) ![Loading](https://www.cmaj.ca/modules/freebird/modules/highwire/highwire_markup/images/tab_loading.gif) [ PDF](https://www.cmaj.ca/content/cmaj/198/39/E1505.full.pdf) [Previous](https://www.cmaj.ca/content/198/39/E1504 "Dermatomyositis")[Next](https://www.cmaj.ca/content/198/39/E1506 "Clinically amyopathic dermatomyositis in a woman with palmar papules and exertional dyspnea") [Back to top](https://www.cmaj.ca/content/198/39/E1505#page) ### In This Issue [![ CMAJ ](https://www.cmaj.ca/sites/default/files/styles/large/public/highwire/cmaj/198/39.cover-source.jpg)](https://www.cmaj.ca/content/198/39 "CMAJ") ### [CMAJ](https://www.cmaj.ca/content/198/39 " CMAJ ") Vol. 198, Issue 39 10 Nov 2026 [ Table of Contents ](https://www.cmaj.ca/content/198/39 "Table of Contents")[ Index by author ](https://www.cmaj.ca/content/198/39/index-by-author "Index by author") ## Article tools * [ Respond to this article ](https://www.cmaj.ca/content/198/39/E1505#tab-group-eletter "Respond to this article") * [ Print ](https://www.cmaj.ca/custom-print/232552) * [ Download PDF ](https://www.cmaj.ca/content/cmaj/198/39/E1505.full.pdf) * [ Article Alerts ](https://www.cmaj.ca/content/198/39/E1505 "Article Alerts") #### Alerts for this Article User Name * Password * To sign up for email alerts or to access your current email alerts, enter your email address below: Email * * [ Email Article ](https://www.cmaj.ca/content/198/39/E1505 "Email This Article") #### Email This Article Thank you for your interest in spreading the word on CMAJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following [Leukemoid reactions](https://www.cmaj.ca/content/198/39/E1505) Message Subject (Your Name) has sent you a message from CMAJ Message Body (Your Name) thought you would like to see the CMAJ web site. Your Personal Message CAPTCHA Please verify that you are a real person Close * [ Citation Tools ](https://www.cmaj.ca/content/198/39/E1505 "Citation Tools") #### Citation Tools ##### Leukemoid reactions * Nickrooz Grami Nickrooz Grami * Helena Dhamko Helena Dhamko * and Wayne L. Gold Wayne L. Gold * CMAJ * November 10, 2026 * 198 * (39) * E1505; * DOI: 10.1503/cmaj.260791 #### Citation Manager Formats * [BibTeX](https://www.cmaj.ca/admin/highwire/citation/232552/bibtext_journal) * [Bookends](https://www.cmaj.ca/admin/highwire/citation/232552/bookend_journal) * [EasyBib](https://www.cmaj.ca/admin/highwire/citation/232552/easybib_journal) * [EndNote (tagged)](https://www.cmaj.ca/admin/highwire/citation/232552/endnote_journal) * [EndNote 8 (xml)](https://www.cmaj.ca/admin/highwire/citation/232552/endnotexml_journal) * [Medlars](https://www.cmaj.ca/admin/highwire/citation/232552/medlars_journal) * [Mendeley](https://www.cmaj.ca/admin/highwire/citation/232552/mendeley_journal) * [Papers](https://www.cmaj.ca/admin/highwire/citation/232552/papers_journal) * [RefWorks Tagged](https://www.cmaj.ca/admin/highwire/citation/232552/refworkstagged_journal) * [Ref Manager](https://www.cmaj.ca/admin/highwire/citation/232552/refmanger_journal) * [RIS](https://www.cmaj.ca/admin/highwire/citation/232552/ris_journal) * [Zotero](https://www.cmaj.ca/admin/highwire/citation/232552/zotero_journal) * [ Request Permissions ](https://www.cmaj.ca/copyright "Request Permissions") * [ Share ](https://www.cmaj.ca/content/198/39/E1505 "Share This Article") #### Share This Article ##### Leukemoid reactions * Nickrooz Grami Nickrooz Grami * Helena Dhamko Helena Dhamko * and Wayne L. Gold Wayne L. Gold * CMAJ * November 10, 2026 * 198 * (39) * E1505; * DOI: 10.1503/cmaj.260791 Share This Article: Copy ![](https://www.cmaj.ca/modules/freebird/modules/custom/jnl_basic_config/images/twitter.png)![](https://www.cmaj.ca/modules/freebird/modules/custom/jnl_basic_config/images/fb-blue.png)![](https://www.cmaj.ca/mod
## Related Clinical Research

- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Creatine for Healthy Aging: Examining a Decade of Use](https://medichelpline.com/clinical-feed/medical-news-today-0-age-appropriate-i-ve-taken-creatine-for-10-years-does-it-help-healthy-aging.md)
- [Heidi Overton FDA Nomination Withdrawn; Merck Stops Nemtabrutinib Program](https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a.md)
- [SARS-CoV-2 antibody landscape after multiple Omicron-era vaccinations and infections](https://medichelpline.com/clinical-feed/medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections.md)
- [Flagship opens biotech-creation outpost in the U.K.; sector updates on Isomorphic and Sellas](https://medichelpline.com/clinical-feed/stat-news-1-stat-flagship-opens-biotech-creation-outpost-in-the-u-k.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.